204 related articles for article (PubMed ID: 1347745)
1. A subdomain in the transmembrane domain is necessary for p185neu* activation.
Cao H; Bangalore L; Bormann BJ; Stern DF
EMBO J; 1992 Mar; 11(3):923-32. PubMed ID: 1347745
[TBL] [Abstract][Full Text] [Related]
2. An extra cysteine proximal to the transmembrane domain induces differential cross-linking of p185neu and p185neu.
Cao H; Bangalore L; Dompé C; Bormann BJ; Stern DF
J Biol Chem; 1992 Oct; 267(28):20489-92. PubMed ID: 1356980
[TBL] [Abstract][Full Text] [Related]
3. Biochemical comparisons of the normal and oncogenic forms of insect cell-expressed neu tyrosine kinases.
Guy PM; Carraway KL; Cerione RA
J Biol Chem; 1992 Jul; 267(20):13851-6. PubMed ID: 1352772
[TBL] [Abstract][Full Text] [Related]
4. An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity.
Ben-Levy R; Peles E; Goldman-Michael R; Yarden Y
J Biol Chem; 1992 Aug; 267(24):17304-13. PubMed ID: 1355090
[TBL] [Abstract][Full Text] [Related]
5. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation.
Burke CL; Lemmon MA; Coren BA; Engelman DM; Stern DF
Oncogene; 1997 Feb; 14(6):687-96. PubMed ID: 9038376
[TBL] [Abstract][Full Text] [Related]
6. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity.
Stern DF; Heffernan PA; Weinberg RA
Mol Cell Biol; 1986 May; 6(5):1729-40. PubMed ID: 2878363
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products.
Kokai Y; Dobashi K; Weiner DB; Myers JN; Nowell PC; Greene MI
Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5389-93. PubMed ID: 2899889
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of tyrosine kinase activity of the Drosophila epidermal growth factor receptor homolog by alterations of the transmembrane domain.
Wides RJ; Zak NB; Shilo BZ
Eur J Biochem; 1990 May; 189(3):637-45. PubMed ID: 1972062
[TBL] [Abstract][Full Text] [Related]
9. A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation.
Lehväslaiho H; Lehtola L; Sistonen L; Alitalo K
EMBO J; 1989 Jan; 8(1):159-66. PubMed ID: 2565807
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma.
Peles E; Levy RB; Or E; Ullrich A; Yarden Y
EMBO J; 1991 Aug; 10(8):2077-86. PubMed ID: 1676673
[TBL] [Abstract][Full Text] [Related]
11. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.
Weiner DB; Kokai Y; Wada T; Cohen JA; Williams WV; Greene MI
Oncogene; 1989 Oct; 4(10):1175-83. PubMed ID: 2571965
[TBL] [Abstract][Full Text] [Related]
12. The effects of the normal and oncogenic forms of the neu tyrosine kinase, and the corresponding forms of an immunoglobulin E receptor/neu tyrosine kinase fusion protein, on Xenopus oocyte maturation.
Narasimhan V; Hamill O; Cerione RA
FEBS Lett; 1992 Jun; 303(2-3):164-8. PubMed ID: 1351469
[TBL] [Abstract][Full Text] [Related]
13. Conformational changes induced by the transforming amino acid substitution in the transmembrane domain of the neu oncogene-encoded p185 protein.
Brandt-Rauf PW; Pincus MR; Chen JM
J Protein Chem; 1989 Dec; 8(6):749-56. PubMed ID: 2576207
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo.
Stern DF; Kamps MP; Cao H
Mol Cell Biol; 1988 Sep; 8(9):3969-73. PubMed ID: 2464744
[TBL] [Abstract][Full Text] [Related]
15. Substitution of the insulin receptor transmembrane domain with the c-neu/erbB2 transmembrane domain constitutively activates the insulin receptor kinase in vitro.
Yamada K; Goncalves E; Kahn CR; Shoelson SE
J Biol Chem; 1992 Jun; 267(18):12452-61. PubMed ID: 1352286
[TBL] [Abstract][Full Text] [Related]
16. Correlation of the structure of the transmembrane domain of the neu oncogene-encoded p185 protein with its function.
Brandt-Rauf PW; Rackovsky S; Pincus MR
Proc Natl Acad Sci U S A; 1990 Nov; 87(21):8660-4. PubMed ID: 1978329
[TBL] [Abstract][Full Text] [Related]
17. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene.
Bargmann CI; Weinberg RA
Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5394-8. PubMed ID: 2899890
[TBL] [Abstract][Full Text] [Related]
18. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.
Weiner DB; Liu J; Cohen JA; Williams WV; Greene MI
Nature; 1989 May; 339(6221):230-1. PubMed ID: 2654648
[TBL] [Abstract][Full Text] [Related]
19. Regulated coupling of the Neu receptor to phosphatidylinositol 3'-kinase and its release by oncogenic activation.
Peles E; Lamprecht R; Ben-Levy R; Tzahar E; Yarden Y
J Biol Chem; 1992 Jun; 267(17):12266-74. PubMed ID: 1351056
[TBL] [Abstract][Full Text] [Related]
20. The neu oncogene encodes an epidermal growth factor receptor-related protein.
Bargmann CI; Hung MC; Weinberg RA
Nature; 1986 Jan 16-22; 319(6050):226-30. PubMed ID: 3945311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
